Blood Clotting Therapies At
THE HEART OF HUMAN RESILIENCE.
Hemab is pioneering the first targeted preventative treatments and functional cures for underserved bleeding and thrombotic disorders—reimagining the standard of care for patients everywhere.
No Patient With A
The First-Ever Preventative Treatments For
*Currently using monovalent and bispecific antibodies, with intention of expanding to other modalities
Preventing The Full Spectrum Of
Leveraging validated advanced technologies and key insights into the biology of clotting, Hemab’s approach is prime for widespread expansion into a range of underserved bleeding and thrombotic disorders, including Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and others.
We are committed to finding and serving patients that have been left behind despite recent innovative therapies. Our strategic guidance, Hemab 1-2-5TM is targeting development of five clinical assets by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, active lives.
If you have questions about our ongoing clinical trials, please contact email@example.com.
Building The Ultimate
Bringing together international experts in clotting biology, patient care, and drug development, the Hemab team is committed to changing the lives of patients with rare clotting disorders all around the world.
Benny Sorensen, MD, PhD CEO
Benny Sorensen, MD, PhD, joined as CEO of Hemab Therapeutics from Codiak Biosciences where he served as Senior Vice President, Head of Clinical Development and Strategic Projects. During his tenure, he was involved with building the company and leading non-clinical, clinical, and regulatory affairs and advancing the first-ever engineered exosome therapeutics from idea into clinical proof of concept. Dr. Sorensen remains a member of the Scientific Advisory Board at Codiak. Before Codiak, he was Senior Director of Clinical Research at Alnylam Pharmaceuticals, where he led development of fitusiran and other hematology products. Previously, he was a Global Medical Director at Baxter Healthcare Corporation advancing pivotal development of Adynovate® and Vonvendi®. He has more than 15 years of experience in clinical and translational research and management. Prior to industry, he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy’s and St. Thomas’ Hospital & King’s College London School of Medicine, where he led basic translational research and advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen earned his MD and PhD in Medicine degrees from Aarhus University, Denmark, and has published extensively in hematology translational and clinical research.
Mads Behrndt, MSc CFO & General Manager
Mads Behrndt, MSc, is CFO and General Manager of Hemab. He brings more than 14 years of experience in the international capital markets as well as within strategy and business development. He joined Hemab from PwC, where he was a Partner at PwC’s Corporate Finance practice. At PwC, he led and executed private and public company financings and M&A transactions. He earned an MSc in Finance & Strategic Management from the Copenhagen Business School, Denmark.
Cécile Bonvoisin, MSc Senior Vice President, CMC and Manufacturing
Cécile Bonvoisin, MSc, serves as Senior Vice President, CMC and Manufacturing of Hemab. She brings more than 20 years of strong operational experience in the pharmaceutical industry, especially in drug substance and drug product development for small molecules, biochemical and biologic products. She started her career at GlaxoSmithKline and joined from Sanofi, where she was the Global Head of Clinical Injectables Manufacturing within Biologics CMC. She also held positions in manufacturing and commercial organizations, leading international teams and strengthened her strategic thinking skills as the “attaché” of the Sanofi ExCom member in charge of Manufacturing and Quality, Supply Chain and EHS global functions. She earned a Master’s Degree in Engineering and an MSc in Process Engineering from the National Engineering School of Chemical Engineering in Toulouse, France.
John Maraganore, PhD Board Chair
John Maraganore, PhD, serves as the Chair of Hemab’s Board of Directors. In his nearly 20-year tenure as the founding CEO of Alnylam, he steered the company’s efforts to pioneer RNA interference (RNAi) therapeutics, raising over $7 billion to fund its programs and establishing partnerships with more than 25 of the leading pharmaceutical and biotechnology companies. As inventor of bivalirudin, a direct-acting thrombin inhibitor later commercialized as ANGIOMAX™, and formative contributor to Fitusiran, an RNAi therapeutic targeting antithrombin for the treatment of hemophilia A or B, he has deep knowledge of thrombosis and hemostasis research and development. He has a PhD in Biochemistry and Molecular Biology from the University of Chicago, United States.
Linda Bain Director
Linda Bain is CFO of Codiak BioSciences. Prior to joining Codiak, she held senior roles at Adverum Biotechnologies (previously Avalanche Biotechnologies), bluebird bio, Genzyme Corporation, Fidelity Investments, and AstraZeneca. Her dedication to health equity will be key to advancing Hemab’s mission to aid underserved patients around the world. She earned a BS and an Honors degree in Accounting and Business Administration from the University of the Free State, South Africa.
Laura Tadvalkar, PhD, MSc Director
Laura Tadvalkar, PhD, MSc, is a Principal on the Venture Team at RA Capital Management. Her primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging early-stage companies. Prior to RA, she was a Principal at MP Healthcare Venture Management. Prior to MP, she was a Consultant at Clarion Healthcare. She has a PhD in Chemical Biology from Harvard University, United States.
Jørgen Søberg Petersen, MD, PhD, DSc, MBA Director
Jørgen Søberg Petersen, MD, PhD, DMSc, MBA, is Hemab’s immediate Past Board Chair. Dr. Pedersen trained in medicine in Denmark and in the United States. During his 20 years in the pharmaceutical industry, he served in executive R&D roles at Lundbeck, Zealand Pharma, Merck, and Novo Nordisk. He co-founded Zealand Pharma and built the company to exit. He has extensive experience in rare disease development and financing of rare disease companies and is currently a Partner at Novo Holdings. He earned an MD, PhD in Pharmacology, and DMSc from the University of Copenhagen, Denmark, and an MBA from the Technical University of Denmark.
Mårten Steen, MD, PhD Director
Mårten Steen, MD, PhD, is a partner of HealthCap. Previously, he worked as a Director of business development at Merck Serono, focusing on both product and technology licensing. Dr. Steen has pursued research in the field of protein chemistry and coagulation disorders at Lund University and Novo Nordisk. He is the author of numerous scientific papers published in peer-reviewed journals. He earned an MD and PhD in Clinical Chemistry from Lund University, Sweden.